(Reuters) -U.S. drugmaker Merck said on Thursday its experimental combination treatment for some adults with HIV-1 infection met the main goal of two late-stage studies. The combination of Merck’s doravirine and islatravir was non-inferior compared to Gilead Sciences’ triple-combination tablet Biktarvy and various other antiretroviral therapies in suppressing replication of the virus, the company